Naamit Sher

Inga fler pågående positioner

71 år

Health Technology

Consumer Services

Profil

Naamit Sher worked as the VP of Drug Development & Regulatory Affairs at Vascular Biogenics Ltd. She was also the Director of Quality Control & Quality Assurance at Interpharm Laboratories Ltd. and the Head of QC Laboratories at Teva Pharmaceutical Industries Ltd. Additionally, she held the title of Principal at Teva North America.
Dr. Sher received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.

Tidigare kända positioner av Naamit Sher

Företag	Position	Slut
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	Företagsledare/Principal	2006-01-01
Teva North America	Företagsledare/Principal	-
Interpharm Laboratories Ltd. Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases	Företagsledare/Principal	-
NOTABLE LABS, LTD.	Generell Rådgivare	-

Se detaljerna i Naamit Shers erfarenhet

Naamit Shers utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i Naamit Shers erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	5
Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients	Health Technology
The Hebrew University of Jerusalem The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Teva North America
Interpharm Laboratories Ltd. Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases	Health Technology
Vascular Biogenics Ltd. Vascular Biogenics Ltd. BiotechnologyHealth Technology Develops novel treatments for atherosclerosis and cancer	Health Technology